ReviewMicrobial biotechnology2012
Vaccination in the elderly.
Review in Microbial biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Age-Related Changes in the Natural Killer Cell Response to Seasonal Influenza Vaccination Are Not Influenced by a Synbiotic: a Randomised Controlled Trial.Frontiers in immunology · 2018Trial
- The immune system as a guardian of health: micronutrient support and lifelong protection.Frontiers in nutrition · 2026Review
- Immunological and Clinical Responses to Vaccinations among Adults Living with HIV.Life (Basel, Switzerland) · 2024Review
- Autovaccine-Based Immunotherapy: A Promising Approach for Male Recurrent Urinary Tract Infections.Life (Basel, Switzerland) · 2024Article
- Vaccine conspiracy association with higher COVID-19 vaccination side effects and negative attitude towards booster COVID-19, influenza and monkeypox vaccines: A pilot study in Saudi Universities.Human vaccines & immunotherapeutics · 2023Article
- Review
- The impact of age-related syndromes on ICU process and outcomes in very old patients.Annals of intensive care · 2023Review
- Impact of COVID-19 in individuals with and without pre-existent digestive disorders with a particular focus on elderly patients.World journal of gastroenterology · 2023Review
- Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals.Communications biology · 2023Article
- Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals.Research square · 2022Article
- Nutrition, Immunosenescence, and Infectious Disease: An Overview of the Scientific Evidence on Micronutrients and on Modulation of the Gut Microbiota.Advances in nutrition (Bethesda, Md.) · 2022Review
- Effect of Influenza Vaccination on the Reduction of the Incidence of Chronic Kidney Disease and Dialysis in Patients with Type 2 Diabetes Mellitus.Journal of clinical medicine · 2022Article
- Psychotropic drugs interaction with the lipid nanoparticle of COVID-19 mRNA therapeutics.Frontiers in pharmacology · 2022Article
- Risk Factors Influencing Seroconversion after Inactive SARS-CoV-2 Vaccination in People Living with Obesity.Obesity facts · 2022Article
- Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis.Vaccines · 2021Review
- Relationships Between Age, Frailty, Length of Care Home Residence and Biomarkers of Immunity and Inflammation in Older Care Home Residents in the United Kingdom.Frontiers in aging · 2021Article
- Older adults: panoramic view on the COVID-19 vaccination.AIMS public health · 2021Review
- A Potential Role for Photobiomodulation Therapy in Disease Treatment and Prevention in the Era of COVID-19.Aging and disease · 2020Article
- Review
- Progress and Pitfalls in the Quest for Effective SARS-CoV-2 (COVID-19) Vaccines.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is a general consensus that the elderly do not respond as well to vaccination as the young, but robust studies are few and far between. Most refer to influenza vaccination, but even here, adequate immunological and clinical data are surprisingly thin on the ground. The meta-analysis by Goodwin et al. from 2006 is still the most comprehensive that we have. They reviewed 31 antibody response studies comparing influenza vaccination efficacy in groups of elderly and younger adults. They reported that the adjusted odds ratio (OR) of responses in elderly versus young adults ranged from 0.24 to 0.59 for the three influenza antigens used in the vaccines. They concluded that rather than the estimated 70-90% clinical vaccine efficacy in younger adults, this figure was only 17-53% in the elderly, depending on which viruses were prevalent that year. They stated that 'this highlights the need for more immunogenic vaccine formulations for the elderly'. How to achieve this? There are three areas where we may consider alterations to increase vaccine efficacy: (i) make the vaccine more potent; (ii) use adjuvants to enhance immunity; and (iii) apply immune modulators or other interventions to alter host immunity generally. We will consider these three options, focusing on influenza vaccination, in this mini-review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.